Oryn Therapeutics (United States)

Batch‐to‐batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial

Elise Burmeister Getz, KJ Carroll, Byron Jones et al. · Clinical Pharmacology & Therapeutics · 2016 · 40 citations · Full text

Drug Analysis, Current Bioequivalence Regulations, Pharmacokinetic Modeling +15

Fungicidal Potency and Mechanisms of θ-Defensins against Multidrug-Resistant Candida Species

Virginia Basso, Angie Garcia, Dat Q. Tran et al. · Antimicrobial Agents and Chemotherapy · 2018 · 36 citations · Full text

Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial

Elise Burmeister Getz, KJ Carroll, Johanna Mielke et al. · Clinical Pharmacology & Therapeutics · 2016 · 21 citations · Full text

Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms

Virginia Basso, Dat Q. Tran, Justin B. Schaal et al. · Scientific Reports · 2019 · 21 citations · Full text

Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide

Justin B. Schaal, Dat Q. Tran, Akshay Subramanian et al. · PLoS ONE · 2017 · 14 citations · Full text

Immunology, Innate Immunity, Parenteral Rtd-1 Treatment +21